• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

如何诊断和测量原发性多汗症:文献系统综述。

How to diagnose and measure primary hyperhidrosis: a systematic review of the literature.

机构信息

Department of Dermatology, Faculty of Health and Medical Sciences, Zealand University Hospital, University of Copenhagen, Copenhagen, Denmark.

出版信息

Clin Auton Res. 2021 Aug;31(4):511-528. doi: 10.1007/s10286-021-00794-6. Epub 2021 Mar 27.

DOI:10.1007/s10286-021-00794-6
PMID:33772671
Abstract

PURPOSE

Hyperhidrosis (i.e. excessive sweating) is diagnosed from patient medical history and physical examination. In addition, focal sweat measurements can substantiate the hyperhidrosis diagnosis. Likewise, the impact of living with hyperhidrosis can be assessed with patient-reported outcome measures. However, no consensus exists on how to diagnose hyperhidrosis, how to quantify the disease, or how to measure the impact hyperhidrosis has on patients. Therefore, the objective of this review was to summarize the literature on diagnostic criteria, focal sweat measurement methods, and patient-reported outcome measures of hyperhidrosis.

METHODS

A literature search of Cochrane Library, Embase, and PubMed was conducted. Studies that included and aimed at developing or validating hyperhidrosis diagnostic criteria, focal sweat measurement methods, or patient-reported outcome measures for individuals with hyperhidrosis were eligible for inclusion. The methodological quality of diagnostic accuracy studies about focal sweat measurement methods was determined using the Quality Assessment of Diagnostic Accuracy Studies-2.

RESULTS

Overall, 33 studies were included. We identified two sets of hyperhidrosis diagnostic criteria, one scale for assessment of severity of hyperhidrosis sweating, four focal sweat measurement methods, and 15 patient-reported outcome measures.

CONCLUSION

The algorithm for diagnosing hyperhidrosis and focal sweat measurement methods needs validation in large cohorts. Most patient-reported outcome measures for hyperhidrosis are not adequately validated. A potential solution is to develop a core outcome set that can standardize outcomes reported in clinical trials.

摘要

目的

多汗症(即过度出汗)通过患者的病史和体格检查来诊断。此外,局部汗液测量可以证实多汗症的诊断。同样,可以使用患者报告的结局测量来评估与多汗症一起生活的影响。然而,目前对于如何诊断多汗症、如何量化该疾病以及如何衡量多汗症对患者的影响,尚无共识。因此,本综述的目的是总结多汗症的诊断标准、局部汗液测量方法和患者报告的结局测量文献。

方法

对 Cochrane 图书馆、Embase 和 PubMed 进行文献检索。符合纳入标准的研究包括旨在开发或验证多汗症诊断标准、局部汗液测量方法或多汗症患者患者报告结局测量的研究。使用诊断准确性研究的质量评估工具-2 来确定局部汗液测量方法的诊断准确性研究的方法学质量。

结果

共纳入 33 项研究。我们确定了两套多汗症诊断标准、一种评估多汗症出汗严重程度的量表、四种局部汗液测量方法和 15 种患者报告的结局测量。

结论

用于诊断多汗症和局部汗液测量方法的算法需要在大样本中进行验证。大多数多汗症患者报告的结局测量都没有得到充分验证。一个潜在的解决方案是开发一个核心结局集,该集可以标准化临床试验中的报告结果。

相似文献

1
How to diagnose and measure primary hyperhidrosis: a systematic review of the literature.如何诊断和测量原发性多汗症:文献系统综述。
Clin Auton Res. 2021 Aug;31(4):511-528. doi: 10.1007/s10286-021-00794-6. Epub 2021 Mar 27.
2
Interventions for promoting habitual exercise in people living with and beyond cancer.促进癌症患者及康复者进行习惯性锻炼的干预措施。
Cochrane Database Syst Rev. 2018 Sep 19;9(9):CD010192. doi: 10.1002/14651858.CD010192.pub3.
3
Eliciting adverse effects data from participants in clinical trials.从临床试验参与者中获取不良反应数据。
Cochrane Database Syst Rev. 2018 Jan 16;1(1):MR000039. doi: 10.1002/14651858.MR000039.pub2.
4
Measures implemented in the school setting to contain the COVID-19 pandemic.学校为控制 COVID-19 疫情而采取的措施。
Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.
5
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
6
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
7
Measurement properties of patient-reported outcome measures (PROMs) in hyperhidrosis: a systematic review.多汗症患者报告结局测量指标(PROMs)的测量特性:系统评价。
Qual Life Res. 2022 Mar;31(3):671-686. doi: 10.1007/s11136-021-02958-3. Epub 2021 Jul 30.
8
Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.染色体臂 1p 和 19q 缺失的检测在胶质瘤患者中的诊断准确性和成本效益。
Cochrane Database Syst Rev. 2022 Mar 2;3(3):CD013387. doi: 10.1002/14651858.CD013387.pub2.
9
Pregabalin add-on for drug-resistant focal epilepsy.普瑞巴林添加治疗耐药性局灶性癫痫。
Cochrane Database Syst Rev. 2022 Mar 29;3(3):CD005612. doi: 10.1002/14651858.CD005612.pub5.
10
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.戈谢病酶替代疗法的临床疗效和成本效益:一项系统评价。
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240.

引用本文的文献

1
Primary hyperhidrosis: From a genetics point of view.原发性多汗症:从遗传学角度来看。
J Family Med Prim Care. 2023 Dec;12(12):3028-3032. doi: 10.4103/jfmpc.jfmpc_1568_22. Epub 2023 Dec 21.
2
PAI1 inhibits the pathogenesis of primary focal hyperhidrosis by targeting CHRNA1.PAI1 通过靶向 CHRNA1 抑制原发性局限性多汗症的发病机制。
Orphanet J Rare Dis. 2023 Jul 21;18(1):205. doi: 10.1186/s13023-023-02808-0.
3
Comparison of CT-guided thoracic sympathetic nerve block and radiofrequency in the treatment of primary palmar hyperhidrosis.

本文引用的文献

1
Primary hyperhidrosis prevalence and characteristics among medical students in Rio de Janeiro.里约热内卢医学生原发性多汗症的患病率和特征。
PLoS One. 2019 Sep 13;14(9):e0220664. doi: 10.1371/journal.pone.0220664. eCollection 2019.
2
Development and validation of the Axillary Sweating Daily Diary: a patient-reported outcome measure to assess axillary sweating severity.腋下出汗日常日记的开发与验证:一种用于评估腋下出汗严重程度的患者报告结局指标。
J Patient Rep Outcomes. 2019 Sep 5;3(1):59. doi: 10.1186/s41687-019-0148-8.
3
Comparison of patient-reported disease severity and sweat measurements in primary focal hyperhidrosis.
CT引导下胸交感神经阻滞与射频治疗原发性手掌多汗症的比较。
Front Surg. 2023 May 31;10:1126596. doi: 10.3389/fsurg.2023.1126596. eCollection 2023.
4
The temporal association of hyperhidrosis and its comorbidities - a nationwide hospital-based cohort study.多汗症及其合并症的时间关联:一项全国性基于医院的队列研究。
J Eur Acad Dermatol Venereol. 2022 Dec;36(12):2504-2511. doi: 10.1111/jdv.18351. Epub 2022 Jul 11.
原发性局灶性多汗症患者报告的疾病严重程度与汗液测量结果的比较。
J Am Acad Dermatol. 2019 Nov;81(5):1209-1211. doi: 10.1016/j.jaad.2019.04.015. Epub 2019 Apr 12.
4
User's guide to correlation coefficients.相关系数用户指南。
Turk J Emerg Med. 2018 Aug 7;18(3):91-93. doi: 10.1016/j.tjem.2018.08.001. eCollection 2018 Sep.
5
Hyperhidrosis: prevalence and impact on quality of life.多汗症:患病率及其对生活质量的影响。
J Bras Pneumol. 2018 Jul-Aug;44(4):292-298. doi: 10.1590/S1806-37562017000000379. Epub 2018 Jul 30.
6
The Hyperhidrosis Disease Severity Measure-Axillary: Conceptualization and Development of Item Content.多汗症疾病严重程度测量——腋窝:项目内容的概念化与开发
J Drugs Dermatol. 2018 Jul 1;17(7):707-714.
7
Update of the S1 guidelines on the definition and treatment of primary hyperhidrosis.S1 指南:原发性多汗症的定义和治疗更新。
J Dtsch Dermatol Ges. 2018 Jul;16(7):945-952. doi: 10.1111/ddg.13579.
8
COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study.COSMIN 方法学用于评估患者报告结局测量的内容效度:一项德尔菲研究。
Qual Life Res. 2018 May;27(5):1159-1170. doi: 10.1007/s11136-018-1829-0. Epub 2018 Mar 17.
9
COSMIN guideline for systematic reviews of patient-reported outcome measures.COSMIN 患者报告结局测量系统评价指南。
Qual Life Res. 2018 May;27(5):1147-1157. doi: 10.1007/s11136-018-1798-3. Epub 2018 Feb 12.
10
COSMIN Risk of Bias checklist for systematic reviews of Patient-Reported Outcome Measures.COSMIN 患者报告结局测量系统评价偏倚风险清单。
Qual Life Res. 2018 May;27(5):1171-1179. doi: 10.1007/s11136-017-1765-4. Epub 2017 Dec 19.